Trial Profile
Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Aug 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 23 Aug 2021 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results assessing the correlation between response to combination therapy and homologous recombination deficiency (n=32), presented at the 42nd European Society for Medical Oncology Congress
- 25 Mar 2017 Status changed from recruiting to active, no longer recruiting.